AI-generated summary
The authors report a randomized, sham-controlled trial of 30 children aged two to six with autism spectrum disorder, who received near-infrared light to the brain twice weekly for eight weeks. The active group showed a larger change in CARS scores than the sham group, and no moderate or severe side effects were reported. The authors state that the results suggest possible benefit and call for larger studies.
- Participants
- 30
- Who or what was studied
- Children aged two to six years with a prior diagnosis of autism spectrum disorder
- Wavelengths
- 850 nm
- Limits stated in the abstract
- The abstract describes a small trial, several EEG findings were only trends or borderline (p = 0.07), and the authors themselves call for larger studies.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Small pilot studies have suggested that transcranial photobiomodulation (tPBM) could help reduce symptoms of neurological conditions, such as depression, traumatic brain injury, and autism spectrum disorder (ASD).
Objective
To examine the impact of tPBM on the symptoms of ASD in children aged two to six years.
Method
We conducted a randomized, sham-controlled clinical trial involving thirty children aged two to six years with a prior diagnosis of ASD. We delivered pulses of near-infrared light (40 Hz, 850 nm) noninvasively to selected brain areas twice a week for eight weeks, using an investigational medical device designed for this purpose (Cognilum™, JelikaLite Corp., New York, United States). We used the Childhood Autism Rating Scale (CARS, 2nd Edition) to assess and compare the ASD symptoms of participants before and after the treatment course. We collected electroencephalogram (EEG) data during each session from those participants who tolerated wearing the EEG cap.
Results
The difference in the change in CARS scores between the two groups was 7.23 (95% CI 2.357 to 12.107, p = 0.011). Seventeen of the thirty participants completed at least two EEGs and time-dependent trends were detected. In addition, an interaction between Active versus Sham and Scaled Time was observed in delta power (Coefficient = 7.521, 95% CI -0.517 to 15.559, p = 0.07) and theta power (Coefficient = -8.287, 95% CI -17.199 to 0.626, p = 0.07), indicating a potential trend towards a greater reduction in delta power and an increase in theta power over time with treatment in the Active group, compared to the Sham group. Furthermore, there was a significant difference in the condition (Treatment vs. Sham) in the power of theta waves (net_theta) (Coefficient = 9.547, 95% CI 0.027 to 19.067, p = 0.049). No moderate or severe side effects or adverse effects were reported or observed during the trial.
Conclusion
These results indicate that tPBM may be a safe and effective treatment for ASD and should be studied in more depth in larger studies. Clinical
Trial Registration
https://clinicaltrials.gov/ct2/show/NCT04660552, identifier NCT04660552.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 850 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Sham, Autism, Photobiomodulation, Electroencephalography, Traumatic brain injury, Trial registration, Near-infrared. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.